Alnylam’s New Hypertension Combo Study Could Reshape Its Long-Term Value

Alnylam Pharmaceuticals (ALNY) announced an update on their ongoing clinical study.

The Phase 2 study “A Phase 2, Randomized, Double-blind, Placebo-controlled, Single Dose Study of the Efficacy, Pharmacodynamics, and Safety of ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran” tests a new add-on therapy for high blood pressure. It aims to show if Alnylam’s approach can deliver longer lasting control than current options, which is key for long term market value.

The trial tests ALN-AGT01 RVR, an injectable RNA based drug, added to the company’s hypertension agent zilebesiran. Patients receive zilebesiran first, then either ALN-AGT01 RVR or a placebo shot to see if the combination lowers blood pressure more and keeps it down for longer.

This is an interventional Phase 2 trial with patients randomly assigned to active drug or placebo. It is double blind with four way masking, so patients, doctors, study staff, and outcome assessors do not know who gets the real drug, and the main goal is to assess treatment benefit and safety.

The study was first submitted on 22 Apr 2026, marking the formal start of enrollment and site setup. The latest update on 13 May 2026 signals the protocol is active and being refined, and key dates for primary and final completion will guide when investors can expect top line data.

For Alnylam (ALNY), positive signals from this trial could strengthen its case in hypertension, a huge and competitive market now led by low cost generics. A promising readout may lift sentiment around its RNA platform and support long term growth expectations despite near term trial and R&D costs.

The collaboration with Hoffmann La Roche adds validation and potential commercial muscle if results are strong. It also raises the bar for smaller RNA rivals and could pressure incumbents if long acting control proves superior in real world use, especially in patients who struggle with daily pills.

Investors should watch for safety and durability of blood pressure control, which will drive how payers and doctors view any premium pricing. Any signs of safety concerns or modest efficacy could cap upside and shift attention back to other assets in Alnylam’s pipeline and the broader cardio renal space.

The study is currently recruiting and remains active, with ongoing updates and further details available on the ClinicalTrials.gov portal under identifier NCT07553442.

To learn more about ALNY’s potential, visit the Alnylam Pharmaceuticals drug pipeline page.